Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Bayer forms gene editing partnership with CRISPR Therapeutics

Published 2015-12-21, 10:10 a/m
Bayer forms gene editing partnership with CRISPR Therapeutics
BAYGN
-

FRANKFURT, Dec 21 (Reuters) - Bayer BAYGn.DE will spend
325 million euros ($353 million) on research into a promising
new gene editing technology as part of a joint venture with
biotech firm CRISPR Therapeutics.
Under the deal, the German drugmaker will pay for the joint
venture's research over the next five years, 300 million euros
in total. The venture will be 50 percent owned by the partners.

Bayer will buy a minority stake in CRISPR Therapeutics for
35 million euros.
CRISPR Therapeutics, headquartered in Basel, Switzerland,
with research operations based in Cambridge, Massachusetts, uses
the so-called CRISPR-Cas9 technology, which has become the
preferred method of gene editing in research labs due to its
ease of use.
CRISPR, which stands for clustered regularly interspaced
short palindromic repeats, allows scientists to edit genes by
using biological "scissors" that operate a bit like a
word-processing programme that can find and replace defects.
The joint venture will look into ways to fix malfunctioning
genes in parts of the body that are at the origin of certain
diseases, such as liver cells that fail to produce blood
coagulation factors, the cause of haemophilia.
If successful, such genetic therapy could cure chronic
diseases that now require life-long drug treatments.
One of the challenges Bayer aims to tackle is how to bring
the gene editing mechanism to the diseased cells.
CRISPR Therapeutics will contribute its gene-editing
technology, while Bayer will make its protein engineering
expertise and knowledge about diseases available.
Bayer has the option to secure exclusive rights to use the
joint venture's intellectual property in the areas of blood
disorders, blindness and congenital heart diseases.
CRISPR Therapeutics will have the exclusive rights to any
technology for human use from the collaboration beyond the three
disease areas, while Bayer will retain the rights for non-human
uses, such as agricultural applications.
($1 = 0.9204 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.